Multiple myeloma - lenalidomide and pomalidomide

The Pharmaceutical Benefits Scheme (PBS) subsidises lenalidomide and pomalidomide for patients with multiple myeloma.

Authority to provide PBS subsidised lenalidomide and pomalidomide to patients with multiple myeloma is available under Section 100 of the National Health Act 1953.

Initial treatment

For initial treatments, the Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lenalidomide and pomalidomide.

Continued treatment

Contact our Complex Drugs Programs enquiry line to obtain authority to continue treatment of a patient with multiple myeloma, who does not have progressive disease, with:

  • lenalidomide as monotherapy or in combination with dexamethasone, or
  • pomalidomide in combination with dexamethasone

Patients must meet the relevant criteria as indicated in the restriction and be eligible for PBS subsidised medicines. Schedule item details

Schedule item details

This medicine is only available to a patient who is attending:

  • an approved private hospital
  • a participating public hospital or
  • a public hospital
The hospital provider number must be included on the application form.
  • day admitted patient
  • non-admitted patient or
  • a patient on discharge
These medicines are not available as PBS subsidised medicines for hospital in-patients.

Dose

Lenalidomide is available as 5 mg, 10 mg, 15 mg or 25 mg capsules in a pack size of 21. The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.

An authority prescription should be written for the strength required, a quantity of 21 capsules and up to 2 repeats.

Pomalidomide is available as 3 mg or 4 mg capsules in a pack size of 21. The recommended starting dose of pomalidomide is 4 mg/day taken orally once daily on days 1 to 21 of repeated 28-day cycles.

An authority prescription should be written for the strength required, a quantity of 21 capsules with two repeats.

Patients receiving lenalidomide or pomalidomide under the PBS listing must be registered in the i-access risk management program.

Lenalidomide and pomalidomide are category X medicines and must not be given to pregnant women. Pregnancy in patients or in the partners of patients must be avoided during treatment, and for at least 4 weeks following cessation of treatment.

Lodging an application

All applications for authority to provide PBS subsidised lenalidomide or pomalidomide treatment for multiple myeloma must be provided in writing.

Complete and return the Multiple myeloma – lenalidomide and pomalidomide Initial PBS authority application Supporting information form (PB158).

We will not consider the application unless the patient and prescriber acknowledgements are completed.

Further information

For more information contact the Complex Drugs Programs enquiry line.

Page last updated: 8 November 2016

This information was printed Sunday 22 January 2017 from humanservices.gov.au/health-professionals/enablers/multiple-myeloma-lenalidomide-and-pomalidomide It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.